Autolus Therapeutics PLC (AUTL)
2.94
+0.10
(+3.52%)
USD |
NASDAQ |
Nov 22, 16:00
2.945
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Cash from Operations (Quarterly): -76.74M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -76.74M |
| June 30, 2024 | -51.08M |
| March 31, 2024 | -40.51M |
| December 31, 2023 | -24.83M |
| September 30, 2023 | -40.19M |
| June 30, 2023 | -38.15M |
| March 31, 2023 | -42.42M |
| December 31, 2022 | -14.57M |
| September 30, 2022 | -31.90M |
| June 30, 2022 | -30.81M |
| March 31, 2022 | -35.03M |
| December 31, 2021 | -9.158M |
| Date | Value |
|---|---|
| September 30, 2021 | -34.75M |
| June 30, 2021 | -36.61M |
| March 31, 2021 | -37.34M |
| December 31, 2020 | -27.73M |
| September 30, 2020 | -39.06M |
| June 30, 2020 | -26.93M |
| March 31, 2020 | -24.03M |
| December 31, 2019 | -33.27M |
| September 30, 2019 | -24.49M |
| June 30, 2019 | -17.21M |
| March 31, 2019 | -26.52M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-76.74M
Minimum
Sep 2024
-9.158M
Maximum
Dec 2021
-34.76M
Average
-34.89M
Median
Cash from Operations (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | -54.45M |
| TC BioPharm (Holdings) PLC | -3.055M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -1.446M |
| Bicycle Therapeutics PLC | -39.83M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -9.589M |
| Cash from Financing (Quarterly) | 0.185M |
| Free Cash Flow | -205.61M |
| Free Cash Flow Per Share (Quarterly) | -0.3244 |
| Free Cash Flow Yield | -30.13% |